Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-05-14 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2018年度权益分派实施的公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2018 annual dividend distribution plan approved at the 2018 Annual General Meeting. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. It also references the shareholders' meeting resolutions and related documents. The document is short (1782 characters) and serves as a formal notice of dividend distribution rather than a full financial report or annual report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2019-05-14 Chinese
关于2019年限制性股票激励计划首次授予登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the first grant registration under the company's 2019 restricted stock incentive plan. It details the decision-making process, the number of shares granted, the grant price, the grant date, the list of recipients, the lock-up periods, performance assessment criteria, capital verification by an accounting firm, changes in share capital, and the impact on controlling shareholders. The document is focused on the issuance and registration of restricted stock as part of an equity incentive plan, which is a capital/financing activity. It is not a full annual or interim report, audit report, or earnings release. It is not a simple announcement of a report publication but a substantive disclosure of a financing event involving share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6277 characters) supports it being a detailed announcement rather than a brief notice.
2019-05-09 Chinese
上海市锦天城律师事务所关于公司2019年限制性股票激励计划调整与授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2019 restricted stock incentive plan adjustment and grant matters of a company. It discusses legal compliance, approvals, authorizations, and conditions related to the stock incentive plan. There are no financial statements, earnings data, or management discussion of financial results. The document is not an announcement of a report but a legal opinion on a specific corporate action related to stock incentives. This type of document does not fit into financial reports, earnings releases, or management reports. It is best classified under Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and securities regulation but does not fit other more specific categories.
2019-04-29 Chinese
上海荣正投资咨询股份有限公司关于公司2019年限制性股票激励计划首次授予事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2019 Restricted Stock Incentive Plan of Xiamen Aide Bio-pharmaceutical Technology Co., Ltd. It details the approval, authorization, and implementation of a stock incentive plan, including the granting of restricted shares, conditions for lifting restrictions, performance targets, and the impact on financial results. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a detailed advisory report on a capital incentive plan, which aligns with the category of Capital/Financing Update (CAP) as it involves stock issuance and equity incentives. The document length is substantial (9947 characters), and it contains substantive content rather than just an announcement or summary. Therefore, the appropriate classification is CAP with high confidence.
2019-04-29 Chinese
关于调整2019年限制性股票激励计划首次授予部分激励对象名单及授予数量的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding adjustments to the 2019 restricted stock incentive plan, specifically changes to the list of incentive recipients and the number of shares granted. It details board and shareholder meeting approvals, independent director opinions, supervisory board opinions, legal opinions, and financial advisor opinions related to the stock incentive plan. The content focuses on corporate governance and management decisions about stock incentives rather than financial results, earnings, or regulatory filings. It is not a full annual or interim report, audit report, earnings release, or legal proceeding update. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement of changes in management incentive plans, which fits best under Board/Management Information (MANG) as it relates to management decisions and board approvals on stock incentive plans.
2019-04-29 Chinese
2019年限制性股票激励计划首次授予部分激励对象名单（调整后）
Remuneration Information Classification · 95% confidence The document is titled as a list of recipients for a 2019 restricted stock incentive plan from Xiamen Aide Biomedical Technology Co., Ltd. It details the allocation of restricted stock to various management and technical personnel, including names, positions, and stock quantities. The document is dated April 29, 2019, and signed by the Board of Directors. There is no financial statement, earnings data, or regulatory certification present. The content focuses on stock incentive allocation to management and key employees, which is a form of remuneration information. Given the detailed listing of stock incentives to executives and key personnel, this fits the Remuneration Information category (DEF 14A). The document length is under 5,000 characters, but it is not merely an announcement of a report; it contains substantive data on stock incentives. Therefore, the appropriate classification is DEF 14A with high confidence.
2019-04-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.